The 30 days after birth, puts LL in BP league:
Post# of 148644
" Further, a single dose of leronlimab-PLS led to complete CCR5 receptor occupancy in mothers and newborns for almost a month after birth."
________
From medical site:
M428L/N434S mutation has been used in the development of Xtend™-EGFR, a humanized version of the anti-EGFR antibody cetuximab.
This paper.....
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855492/